anticoagulant in COVID 19 hospitalized - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias death D28detailed results RAPID (Sholzberg), 2021 0.22 [0.07; 0.67]
0.22 [0.07 ; 0.67 ] RAPID (Sholzberg), 2021 1 0% 465 NA not evaluable death or transfer to ICUdetailed results RAPID (Sholzberg), 2021 0.70 [0.44; 1.12]
0.70 [0.44 ; 1.12 ] RAPID (Sholzberg), 2021 1 0% 465 NA not evaluable deathsdetailed results ATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients), 2021 0.88 [0.64; 1.20]
COALIZAO ACTION, 2021 1.55 [0.90; 2.70]
INSPIRATION, 2021 1.09 [0.78; 1.53]
RAPID (Sholzberg), 2021 0.22 [0.07; 0.67]
REMAP-CAP, ACTIV-4a, ATTACC (critically ill patients), 2021 1.08 [0.85; 1.38]
0.99 [0.74 ; 1.33 ] ATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients), 2021, COALIZAO ACTION, 2021, INSPIRATION, 2021, RAPID (Sholzberg), 2021, REMAP-CAP, ACTIV-4a, ATTACC (critically ill patients), 2021 5 63% 4,965 moderate not evaluable clinical deteriorationdetailed results COALIZAO ACTION, 2021 1.35 [0.85; 2.15]
RAPID (Sholzberg), 2021 0.69 [0.43; 1.10]
0.97 [0.50 ; 1.86 ] COALIZAO ACTION, 2021, RAPID (Sholzberg), 2021 2 75% 1,080 moderate not evaluable clinical improvementdetailed results REMAP-CAP, ACTIV-4a, ATTACC (critically ill patients), 2021 0.83 [0.67; 1.03]
0.83 [0.67 ; 1.03 ] REMAP-CAP, ACTIV-4a, ATTACC (critically ill patients), 2021 1 0% 1,074 NA not evaluable clinical improvement (28-day)detailed results ATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients), 2021 1.27 [1.03; 1.57]
1.27 [1.03 ; 1.57 ] ATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients), 2021 1 0% 2,219 NA not evaluable death or ventilationdetailed results ATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients), 2021 0.82 [0.63; 1.07]
RAPID (Sholzberg), 2021 0.59 [0.34; 1.02]
0.76 [0.58 ; 1.00 ] ATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients), 2021, RAPID (Sholzberg), 2021 2 11% 2,696 moderate not evaluable mechanical ventilationdetailed results RAPID (Sholzberg), 2021 0.70 [0.32; 1.54]
0.70 [0.32 ; 1.54 ] RAPID (Sholzberg), 2021 1 0% 465 NA not evaluable ICU admissiondetailed results RAPID (Sholzberg), 2021 0.79 [0.48; 1.30]
0.79 [0.48 ; 1.30 ] RAPID (Sholzberg), 2021 1 0% 465 NA not evaluable Major thrombotic events or deathdetailed results REMAP-CAP, ACTIV-4a, ATTACC (critically ill patients), 2021 1.04 [0.80; 1.36]
1.04 [0.80 ; 1.36 ] REMAP-CAP, ACTIV-4a, ATTACC (critically ill patients), 2021 1 0% 1,091 NA not evaluable Major bleedingdetailed results ATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients), 2021 1.80 [0.88; 3.67]
COALIZAO ACTION, 2021 2.50 [0.78; 8.06]
INSPIRATION, 2021 1.83 [0.53; 6.34]
REMAP-CAP, ACTIV-4a, ATTACC (critically ill patients), 2021 1.48 [0.74; 2.98]
1.75 [1.14 ; 2.69 ] ATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients), 2021, COALIZAO ACTION, 2021, INSPIRATION, 2021, REMAP-CAP, ACTIV-4a, ATTACC (critically ill patients), 2021 4 0% 4,494 moderate not evaluable Thromboembolic eventsdetailed results COALIZAO ACTION, 2021 0.73 [0.41; 1.29]
INSPIRATION, 2021 1.07 [0.76; 1.49]
0.95 [0.68 ; 1.34 ] COALIZAO ACTION, 2021, INSPIRATION, 2021 2 21% 1,176 moderate not evaluable 0.0 5.0 1.0 relative treatment effect www.metaEvidence.org 2024-04-19 18:38 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 95,94,90,91
- treatments: 608,830,831,829,901,680,595,828,681,1209,833
- roots T: 290
